Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference
Ionis Pharmaceuticals (Nasdaq: IONS) has announced that CEO Brett P. Monia, Ph.D., will deliver a company overview presentation at the 43rd Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ionis Pharmaceuticals (Nasdaq: IONS) has announced that CEO Brett P. Monia, Ph.D., will deliver a company overview presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2025, at 10:30 a.m. PT.
Investors and interested parties can access a live webcast of the presentation through the Investors & Media section of the Ionis website. The presentation recording will be made available on the company's website within 48 hours and will remain accessible for a time.
Details
News Market Reaction – IONS
The recorded move for IONS in the trading session of this news was -1.88%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the presentation can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events. A replay will be available on the Ionis website within 48 hours and will be archived for a limited time.
About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.
To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) and LinkedIn.
Ionis Investor Contact: D. Wade Walke, Ph.D., ir@ionis.com – 760-603-2331
Ionis Media Contact: Hayley Soffer, media@ionis.com – 760-603-4679
View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-present-at-43rd-annual-jp-morgan-healthcare-conference-302346348.html
SOURCE Ionis Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.